Article
Non-small-cell lung cancer harbouring mutations in the EGFR kinase domain.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico - 1 Feb 2010
Rosell Rafael, Morán Teresa, Carcereny Enric, Quiroga Vanessa, Molina Miguel Angel, Costa Carlota, Benlloch Susana, Tarón Miquel
Abstract excerpt
Key "driver" mutations have been discovered in specific subgroups of non-small-cell lung cancer (NSCLC) patients. Activating mutations in the form of deletions in exon 19 (del 19) or the missense mutation L858R in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) predict outcome to EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib. Pooled data from several phase II...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.